{"id":211,"date":"2023-11-30T11:32:00","date_gmt":"2023-11-30T17:32:00","guid":{"rendered":"https:\/\/www.rqmplus.com\/?post_type=scb-resources&#038;p=211"},"modified":"2025-06-05T15:49:27","modified_gmt":"2025-06-05T20:49:27","slug":"a-new-era-of-ldt-oversight-adapting-to-fda-regulations","status":"publish","type":"scb-resources","link":"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/","title":{"rendered":"A New Era of LDT Oversight: Adapting to FDA Regulations"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" width=\"960\" height=\"540\" src=\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2024\/05\/RQM_Live_74_Promo_On_Demand.webp\" alt=\"recorded 20 nov. 2023 a new era of ldt oversight adapting to fda regulations live #74\" class=\"wp-image-264\" style=\"width:550px\" srcset=\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2024\/05\/RQM_Live_74_Promo_On_Demand.webp 960w, https:\/\/www.rqmplus.com\/wp-content\/uploads\/2024\/05\/RQM_Live_74_Promo_On_Demand-300x169.webp 300w, https:\/\/www.rqmplus.com\/wp-content\/uploads\/2024\/05\/RQM_Live_74_Promo_On_Demand-768x432.webp 768w\" sizes=\"(max-width: 960px) 100vw, 960px\" \/><\/figure>\n\n\n\n<p>Laboratory Developed Tests (LDTs) in the U.S. are currently at a pivotal moment. Traditionally, these tests have been under enforcement discretion, but the FDA is now proposing significant regulatory changes.<\/p>\n\n\n\n<p>Over the next five years, the FDA aims to phase out this discretion, introducing a framework that requires comprehensive submissions from LDT providers. This move aligns with the recent EU IVDR implementation, which brought similar oversight to LDTs and all In Vitro Diagnostics (IVDs) in Europe.<\/p>\n\n\n\n<p>Interestingly, the U.S. proposal has already generated substantial feedback, with over a thousand comments submitted, many expressing opposition to the new regulations.<\/p>\n\n\n\n<p>The panel explores the following critical aspects of this evolving regulatory landscape:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Impact Assessment:<\/strong>\u00a0We&#8217;ll explore the potential repercussions of the U.S.&#8217;s proposed LDT regulations.<\/li>\n\n\n\n<li><strong>Regulatory Timeline:<\/strong>\u00a0Gain insights into the rule-making process and the expected timeline for implementation.<\/li>\n\n\n\n<li><strong>EU&#8217;s Response:<\/strong>\u00a0Learn how companies in the EU have adapted to increased oversight of LDTs.<\/li>\n\n\n\n<li><strong>Preparation Strategies:<\/strong>\u00a0Discuss proactive measures that can be taken in anticipation of these changes.<\/li>\n\n\n\n<li><strong>Challenges Ahead:<\/strong>\u00a0Identify the major hurdles companies might face during this transition.<\/li>\n\n\n\n<li><strong>Market Dynamics:<\/strong>\u00a0Evaluate whether this represents an opportunity for IVD manufacturers to expand their market share, especially as smaller labs grapple with meeting the FDA&#8217;s new expectations.<\/li>\n<\/ul>\n\n\n\n<p>This session promises to be an enlightening exploration of the future of LDT regulation and its impact on the MedTech industry.<\/p>\n\n\n\n<p><strong>Please watch now by completing the form.<\/strong><\/p>\n\n\n\n<p>Panelists:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Nancy Morrison, RAC \u2013 Vice President, Intelligence &amp; Innovation<\/li>\n\n\n\n<li>Margot Borgel, Ph.D.\u00a0\u2013 Director, IVD Intelligence &amp; Innovation<\/li>\n\n\n\n<li>Eila Pattee, Principal Consultant<\/li>\n\n\n\n<li>Andrew Lakey, Ph.D. \u2013 Senior Consultant<\/li>\n\n\n\n<li>Theresa Miles \u2013 VP, Client Portfolio Management (moderator)<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Laboratory Developed Tests (LDTs) in the U.S. are currently at a pivotal moment. Traditionally, these tests have been under enforcement&#8230;<\/p>\n","protected":false},"author":2,"featured_media":157,"template":"","meta":{"_acf_changed":false,"_links_to":"","_links_to_target":""},"resource-type":[6],"topic":[9],"class_list":["post-211","scb-resources","type-scb-resources","status-publish","has-post-thumbnail","hentry","resource-type-rqm-live","topic-regulatory-quality"],"acf":[],"card_info":{"title":"A New Era of LDT Oversight: Adapting to FDA Regulations","link":"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/","link_target":"_self","name":"RQM+ Live!","slug":"rqm-live","thumbnail":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/01\/AdobeStock_334138696.jpg","excerpt":"Laboratory Developed Tests (LDTs) in the U.S. are currently at a pivotal moment. Traditionally, these tests have been under enforcement...","display_date":"November 30, 2023"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FDA&#039;s Proposed LDT Regulations: Navigating the New Oversight Era | RQM+<\/title>\n<meta name=\"description\" content=\"Watch our on-demand panel discussion to understand the FDA&#039;s proposed regulatory changes for Laboratory Developed Tests (LDTs) and learn strategies for adapting to the evolving landscape.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA&#039;s Proposed LDT Regulations: Navigating the New Oversight Era | RQM+\" \/>\n<meta property=\"og:description\" content=\"Watch our on-demand panel discussion to understand the FDA&#039;s proposed regulatory changes for Laboratory Developed Tests (LDTs) and learn strategies for adapting to the evolving landscape.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/\" \/>\n<meta property=\"og:site_name\" content=\"RQM+\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RQMplus\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-05T20:49:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/01\/AdobeStock_334138696.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1800\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@RQMplus\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/\",\"url\":\"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/\",\"name\":\"FDA's Proposed LDT Regulations: Navigating the New Oversight Era | RQM+\",\"isPartOf\":{\"@id\":\"https:\/\/www.rqmplus.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/01\/AdobeStock_334138696.jpg\",\"datePublished\":\"2023-11-30T17:32:00+00:00\",\"dateModified\":\"2025-06-05T20:49:27+00:00\",\"description\":\"Watch our on-demand panel discussion to understand the FDA's proposed regulatory changes for Laboratory Developed Tests (LDTs) and learn strategies for adapting to the evolving landscape.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/#primaryimage\",\"url\":\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/01\/AdobeStock_334138696.jpg\",\"contentUrl\":\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/01\/AdobeStock_334138696.jpg\",\"width\":1800,\"height\":1200,\"caption\":\"Pulse monitor on someone's finger.\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.rqmplus.com\/#website\",\"url\":\"https:\/\/www.rqmplus.com\/\",\"name\":\"RQM+\",\"description\":\"Evolving MedTech\",\"publisher\":{\"@id\":\"https:\/\/www.rqmplus.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.rqmplus.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.rqmplus.com\/#organization\",\"name\":\"RQM+\",\"url\":\"https:\/\/www.rqmplus.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.rqmplus.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/02\/logo.png\",\"contentUrl\":\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/02\/logo.png\",\"width\":696,\"height\":696,\"caption\":\"RQM+\"},\"image\":{\"@id\":\"https:\/\/www.rqmplus.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/RQMplus\",\"https:\/\/x.com\/RQMplus\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA's Proposed LDT Regulations: Navigating the New Oversight Era | RQM+","description":"Watch our on-demand panel discussion to understand the FDA's proposed regulatory changes for Laboratory Developed Tests (LDTs) and learn strategies for adapting to the evolving landscape.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/","og_locale":"en_US","og_type":"article","og_title":"FDA's Proposed LDT Regulations: Navigating the New Oversight Era | RQM+","og_description":"Watch our on-demand panel discussion to understand the FDA's proposed regulatory changes for Laboratory Developed Tests (LDTs) and learn strategies for adapting to the evolving landscape.","og_url":"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/","og_site_name":"RQM+","article_publisher":"https:\/\/www.facebook.com\/RQMplus","article_modified_time":"2025-06-05T20:49:27+00:00","og_image":[{"width":1800,"height":1200,"url":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/01\/AdobeStock_334138696.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@RQMplus","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/","url":"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/","name":"FDA's Proposed LDT Regulations: Navigating the New Oversight Era | RQM+","isPartOf":{"@id":"https:\/\/www.rqmplus.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/#primaryimage"},"image":{"@id":"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/01\/AdobeStock_334138696.jpg","datePublished":"2023-11-30T17:32:00+00:00","dateModified":"2025-06-05T20:49:27+00:00","description":"Watch our on-demand panel discussion to understand the FDA's proposed regulatory changes for Laboratory Developed Tests (LDTs) and learn strategies for adapting to the evolving landscape.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rqmplus.com\/resources\/a-new-era-of-ldt-oversight-adapting-to-fda-regulations\/#primaryimage","url":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/01\/AdobeStock_334138696.jpg","contentUrl":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/01\/AdobeStock_334138696.jpg","width":1800,"height":1200,"caption":"Pulse monitor on someone's finger."},{"@type":"WebSite","@id":"https:\/\/www.rqmplus.com\/#website","url":"https:\/\/www.rqmplus.com\/","name":"RQM+","description":"Evolving MedTech","publisher":{"@id":"https:\/\/www.rqmplus.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rqmplus.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.rqmplus.com\/#organization","name":"RQM+","url":"https:\/\/www.rqmplus.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rqmplus.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/02\/logo.png","contentUrl":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/02\/logo.png","width":696,"height":696,"caption":"RQM+"},"image":{"@id":"https:\/\/www.rqmplus.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RQMplus","https:\/\/x.com\/RQMplus"]}]}},"_links":{"self":[{"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/scb-resources\/211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/scb-resources"}],"about":[{"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/types\/scb-resources"}],"author":[{"embeddable":true,"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/users\/2"}],"version-history":[{"count":0,"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/scb-resources\/211\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/media\/157"}],"wp:attachment":[{"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/media?parent=211"}],"wp:term":[{"taxonomy":"resource-type","embeddable":true,"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/resource-type?post=211"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/topic?post=211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}